Linked Life Data

17531336

Source:http://linkedlifedata.com/resource/pubmed/id/17531336

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-6-20
pubmed:abstractText
The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of human malignancies and its expression is associated with tumour aggressiveness and treatment resistance. The monoclonal antibody cetuximab (IMC-C225) blocks the ligand-binding domain of EGFR with high affinity, preventing downstream signalling resulting in tumour growth inhibition. We developed and characterized a novel imaging probe using Oregon Green 488 labelled cetuximab to evaluate its usage as an imaging agent to target EGFR.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0167-8140
pubmed:author
pubmed:issnType
Print
pubmed:volume
83
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
326-32
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII.
pubmed:affiliation
Department of Radiation Oncology (MAASTRO), GROW Research Institute, University of Maastricht, The Netherlands. Hugo.Aerts@maastro.nl
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Evaluation Studies